IOL Chemicals & Pharmaceuticals Ltd — earnings calls

IOL Chemicals and Pharmaceuticals reported its highest-ever quarterly revenue in Q4 FY26 at Rs 619 crore, up 17.4% year-on-year, with EBITDA growing nearly 40% to Rs 94 crore and margin improving to 15.2%. For the full year, revenue rose 11.5% to Rs 2,319 crore, EBITDA increased around 29% to Rs 290 crore, and profit after tax grew about 36% to Rs 138 crore. Management attributed the improvement to operational efficiencies, improved product mix, higher capacity utilisation across ibuprofen and non-ibuprofen APIs, and price increases in the chemical business.